
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune is a promising biopharmaceutical company with a robust portfolio of programs focused on developing effective treatments for neurodegenerative diseases. Its use of proprietary technology platforms provides an advantage in discovering and developing innovative therapies for Alzheimer's and Parkinson's diseases. With a strong pipeline consisting of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others, as well as promising financials and partnerships with top pharmaceutical companies like Takeda, AC Immune is well positioned for success in the neurodegenerative disease market.
Bears say
AC Immune is a clinical stage biopharmaceutical company with a focus on Precision Medicine for neurodegenerative diseases, using technology platforms to develop therapeutic and diagnostic products targeting misfolded proteins. Their current pipeline includes several potential treatments, with key programs ACI-24.060 and ACI-35.030 targeting MCI and preclinical AD, respectively. However, despite the potential for market entry in 2030-2031 with estimated pricing of $26,500 per patient per year, the limited success and challenges faced in their AD4 Cohort suggest a high level of risk for investors.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares